Bbva Compass Bancshares Inc. increased its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 86.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,890 shares of the company’s stock after acquiring an additional 12,022 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Henry Schein were worth $2,123,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in HSIC. Wellington Management Group LLP boosted its position in Henry Schein by 116.0% during the first quarter. Wellington Management Group LLP now owns 13,386 shares of the company’s stock worth $2,275,000 after purchasing an additional 7,189 shares in the last quarter. Teachers Advisors LLC lifted its position in shares of Henry Schein by 3.3% in the first quarter. Teachers Advisors LLC now owns 145,772 shares of the company’s stock valued at $24,777,000 after acquiring an additional 4,595 shares in the last quarter. Thrivent Financial For Lutherans lifted its position in shares of Henry Schein by 2.8% in the first quarter. Thrivent Financial For Lutherans now owns 2,890 shares of the company’s stock valued at $491,000 after acquiring an additional 80 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Henry Schein by 0.6% in the first quarter. Dimensional Fund Advisors LP now owns 310,134 shares of the company’s stock valued at $52,714,000 after acquiring an additional 1,831 shares in the last quarter. Finally, Bank of Nova Scotia lifted its position in shares of Henry Schein by 927.6% in the first quarter. Bank of Nova Scotia now owns 18,137 shares of the company’s stock valued at $3,083,000 after acquiring an additional 16,372 shares in the last quarter. 47.48% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have recently issued reports on HSIC. Credit Suisse Group restated a “hold” rating and issued a $80.00 price objective on shares of Henry Schein in a research report on Thursday, July 13th. Jefferies Group LLC restated a “hold” rating and issued a $89.00 price objective on shares of Henry Schein in a research report on Friday, October 20th. Royal Bank Of Canada began coverage on Henry Schein in a research report on Tuesday, September 19th. They issued a “sector perform” rating and a $91.00 price objective on the stock. Stifel Nicolaus restated a “hold” rating on shares of Henry Schein in a research report on Thursday, July 6th. Finally, Morgan Stanley began coverage on Henry Schein in a research report on Thursday, September 21st. They issued an “equal weight” rating and a $88.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $92.89.
In related news, SVP Paul Rose sold 2,126 shares of Henry Schein stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $172.51, for a total transaction of $366,756.26. Following the completion of the sale, the senior vice president now owns 17,841 shares of the company’s stock, valued at $3,077,750.91. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.19% of the stock is currently owned by company insiders.
Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.02. The firm had revenue of $3.06 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The business’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.82 earnings per share.
Henry Schein announced that its board has initiated a share repurchase plan on Monday, September 18th that permits the company to buyback $400.00 million in shares. This buyback authorization permits the company to reacquire up to 6.3% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
What are top analysts saying about Henry Schein Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Henry Schein Inc. and related companies.